Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR33 vs Insulin Degludec in T2DM Inadequately Controlled With Oral Antidiabetic Drugs
NCT07527078Phase 3Recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Apr 2026
- Primary completion
- Apr 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of GZR33 in type 2 diabetes mellitus (T2DM), sponsored by Gan & Lee Pharmaceuticals. Started Apr 2026; status: recruiting.
02
Drugs
GZR33
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07527078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07527078.